Cargando…

Systemic TLR2 tolerance enhances central nervous system remyelination

BACKGROUND: Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by both inflammatory demyelination and impaired remyelination. Studies indicate that Toll-like receptor 2 (TLR2) signaling contributes to both the inflammatory component and the defective remyelina...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasko, Nicholas J., Kulak, Meghan Horne, Paul, Debayon, Nicaise, Alexandra M., Yeung, Stephen T., Nichols, Frank C., Khanna, Kamal M., Crocker, Stephen, Pachter, Joel S., Clark, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660683/
https://www.ncbi.nlm.nih.gov/pubmed/31351476
http://dx.doi.org/10.1186/s12974-019-1540-2
_version_ 1783439349057060864
author Wasko, Nicholas J.
Kulak, Meghan Horne
Paul, Debayon
Nicaise, Alexandra M.
Yeung, Stephen T.
Nichols, Frank C.
Khanna, Kamal M.
Crocker, Stephen
Pachter, Joel S.
Clark, Robert B.
author_facet Wasko, Nicholas J.
Kulak, Meghan Horne
Paul, Debayon
Nicaise, Alexandra M.
Yeung, Stephen T.
Nichols, Frank C.
Khanna, Kamal M.
Crocker, Stephen
Pachter, Joel S.
Clark, Robert B.
author_sort Wasko, Nicholas J.
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by both inflammatory demyelination and impaired remyelination. Studies indicate that Toll-like receptor 2 (TLR2) signaling contributes to both the inflammatory component and the defective remyelination in MS. While most MS therapeutics target adaptive immunity, we recently reported that reducing TLR2 signaling in innate immune cells by inducing TLR2 tolerance attenuates adoptively transferred experimental autoimmune encephalomyelitis. Given that previous reports suggest TLR2 signaling also inhibits myelin repair, the objective of this study was to assess how reducing TLR2 signaling through TLR2 tolerance induction affects CNS myelin repair. METHODS: Chow containing 0.2% cuprizone was fed to male and female wild-type (WT) C57BL/6 mice or TLR2-deficient (TLR2(−/−)) mice for 5 weeks to induce demyelination. During a 2-week remyelination period following discontinuation of cuprizone, WT mice received either low dose TLR2 ligands to induce systemic TLR2 tolerance or vehicle control (VC). Remyelination was evaluated via electron microscopy and immunohistochemical analysis of microglia and oligodendrocytes in the corpus callosum. Statistical tests included 2-way ANOVA and Mann-Whitney U analyses. RESULTS: Inducing TLR2 tolerance in WT mice during remyelination significantly enhanced myelin recovery, restoring unmyelinated axon frequency and myelin thickness to baseline levels compared to VC-treated mice. Mechanistically, enhanced remyelination in TLR2 tolerized mice was associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS(+) phenotype to a non-inflammatory/pro-repair Arg1(+) phenotype. This result was confirmed in vitro by inducing TLR2 tolerance in WT microglia cultures. TLR2(−/−) mice, without TLR2 tolerance induction, also significantly enhanced myelin recovery compared to WT mice, adding confirmation that reduced TLR2 signaling is associated with enhanced remyelination. DISCUSSION: Our results suggest that reducing TLR2 signaling in vivo by inducing TLR2 tolerance significantly enhances myelin repair. Furthermore, the enhanced remyelination resulting from TLR2 tolerance induction is associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS(+) phenotype to a non-inflammatory/pro-repair Arg1(+) phenotype. While deletion of TLR2 would be an impractical approach in vivo, reducing innate immune signaling through TLR2 tolerance induction may represent a novel, two-pronged approach for treating both inflammatory and myelin repair components of MS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-019-1540-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6660683
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66606832019-08-01 Systemic TLR2 tolerance enhances central nervous system remyelination Wasko, Nicholas J. Kulak, Meghan Horne Paul, Debayon Nicaise, Alexandra M. Yeung, Stephen T. Nichols, Frank C. Khanna, Kamal M. Crocker, Stephen Pachter, Joel S. Clark, Robert B. J Neuroinflammation Research BACKGROUND: Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by both inflammatory demyelination and impaired remyelination. Studies indicate that Toll-like receptor 2 (TLR2) signaling contributes to both the inflammatory component and the defective remyelination in MS. While most MS therapeutics target adaptive immunity, we recently reported that reducing TLR2 signaling in innate immune cells by inducing TLR2 tolerance attenuates adoptively transferred experimental autoimmune encephalomyelitis. Given that previous reports suggest TLR2 signaling also inhibits myelin repair, the objective of this study was to assess how reducing TLR2 signaling through TLR2 tolerance induction affects CNS myelin repair. METHODS: Chow containing 0.2% cuprizone was fed to male and female wild-type (WT) C57BL/6 mice or TLR2-deficient (TLR2(−/−)) mice for 5 weeks to induce demyelination. During a 2-week remyelination period following discontinuation of cuprizone, WT mice received either low dose TLR2 ligands to induce systemic TLR2 tolerance or vehicle control (VC). Remyelination was evaluated via electron microscopy and immunohistochemical analysis of microglia and oligodendrocytes in the corpus callosum. Statistical tests included 2-way ANOVA and Mann-Whitney U analyses. RESULTS: Inducing TLR2 tolerance in WT mice during remyelination significantly enhanced myelin recovery, restoring unmyelinated axon frequency and myelin thickness to baseline levels compared to VC-treated mice. Mechanistically, enhanced remyelination in TLR2 tolerized mice was associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS(+) phenotype to a non-inflammatory/pro-repair Arg1(+) phenotype. This result was confirmed in vitro by inducing TLR2 tolerance in WT microglia cultures. TLR2(−/−) mice, without TLR2 tolerance induction, also significantly enhanced myelin recovery compared to WT mice, adding confirmation that reduced TLR2 signaling is associated with enhanced remyelination. DISCUSSION: Our results suggest that reducing TLR2 signaling in vivo by inducing TLR2 tolerance significantly enhances myelin repair. Furthermore, the enhanced remyelination resulting from TLR2 tolerance induction is associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS(+) phenotype to a non-inflammatory/pro-repair Arg1(+) phenotype. While deletion of TLR2 would be an impractical approach in vivo, reducing innate immune signaling through TLR2 tolerance induction may represent a novel, two-pronged approach for treating both inflammatory and myelin repair components of MS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-019-1540-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-27 /pmc/articles/PMC6660683/ /pubmed/31351476 http://dx.doi.org/10.1186/s12974-019-1540-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wasko, Nicholas J.
Kulak, Meghan Horne
Paul, Debayon
Nicaise, Alexandra M.
Yeung, Stephen T.
Nichols, Frank C.
Khanna, Kamal M.
Crocker, Stephen
Pachter, Joel S.
Clark, Robert B.
Systemic TLR2 tolerance enhances central nervous system remyelination
title Systemic TLR2 tolerance enhances central nervous system remyelination
title_full Systemic TLR2 tolerance enhances central nervous system remyelination
title_fullStr Systemic TLR2 tolerance enhances central nervous system remyelination
title_full_unstemmed Systemic TLR2 tolerance enhances central nervous system remyelination
title_short Systemic TLR2 tolerance enhances central nervous system remyelination
title_sort systemic tlr2 tolerance enhances central nervous system remyelination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660683/
https://www.ncbi.nlm.nih.gov/pubmed/31351476
http://dx.doi.org/10.1186/s12974-019-1540-2
work_keys_str_mv AT waskonicholasj systemictlr2toleranceenhancescentralnervoussystemremyelination
AT kulakmeghanhorne systemictlr2toleranceenhancescentralnervoussystemremyelination
AT pauldebayon systemictlr2toleranceenhancescentralnervoussystemremyelination
AT nicaisealexandram systemictlr2toleranceenhancescentralnervoussystemremyelination
AT yeungstephent systemictlr2toleranceenhancescentralnervoussystemremyelination
AT nicholsfrankc systemictlr2toleranceenhancescentralnervoussystemremyelination
AT khannakamalm systemictlr2toleranceenhancescentralnervoussystemremyelination
AT crockerstephen systemictlr2toleranceenhancescentralnervoussystemremyelination
AT pachterjoels systemictlr2toleranceenhancescentralnervoussystemremyelination
AT clarkrobertb systemictlr2toleranceenhancescentralnervoussystemremyelination